14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 28, 2025
CHEK vs CLSD: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
CHEK Wins Head-to-Head Institutional Verdict (2–2 across 6 Pillars · 6–0 Matrix Metrics)
CHEK Overall Winner
6-Pillar Tally: CHEK 2 – 2 CLSD (2 Tie)
Matrix Metrics: CHEK 6 – 0 CLSD
As of Nov 28, 2025, Check-Cap Ltd. (CHEK) is the stronger overall head-to-head candidate over Clearside Biomedical, Inc. (CLSD) in the Tradestie Institutional Equity Comparison Engine, winning 6–0 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality). CHEK carries a Unified Composite Score of 52.1/100 (HOLD) at $1.61 (N/M Forward P/E, 0.0% operating margin), whereas CLSD carries 43.3/100 (HOLD) at $0.41 (N/M Forward P/E, -3502.5% operating margin).
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CHEK vs CLSD. Trailing 12-month operating profitability (CHEK 0.0% vs CLSD -3502.5%) and valuation multiples (CHEK N/M vs CLSD N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Pharmaceutical Preparations value chain with $2.9M market capitalization and -3502.5% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ CHEK vs CLSD Key Questions & Quantitative Answers
As of Nov 28, 2025, Check-Cap Ltd. (CHEK) is the stronger overall head-to-head candidate over Clearside Biomedical, Inc. (CLSD) in the Tradestie Institutional Equity Comparison Engine, winning 6–0 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality). CHEK carries a Unified Composite Score of 52.1/100 (HOLD) at $1.61 (N/M Forward P/E, 0.0% operating margin), whereas CLSD carries 43.3/100 (HOLD) at $0.41 (N/M Forward P/E, -3502.5% operating margin). Technically, CHEK sits in a Neutral phase (RSI 51.0, UNCLASSIFIED options structure) and CLSD sits in a Neutral phase (RSI 17.4, UNCLASSIFIED options structure).
CHEK leads the Growth & Scale pillar: CHEK posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with CLSD at -80.6% YoY revenue growth and +0.0% YoY earnings growth on $3.3M TTM revenue (88.1% gross margin, -3502.5% operating margin). On trailing 12-month operating scale, CHEK generates N/A in USD-normalized revenue versus $3.3M for CLSD. In operating R&D and SG&A reinvestment, CHEK deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CLSD.
CLSD screens cheaper on headline valuation multiples. CHEK trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas CLSD trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.9x EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CHEK (-226.2% ROE) versus CLSD (-1310.0% ROE) capital efficiency.
In options market volatility and institutional positioning, CHEK carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.94β · 179% Vol realized risk). By comparison, CLSD carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.24β · 269% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 28, 2025. For educational research only; not investment advice.